Finance

Lists
Why is VSTM up 7.66%?
Dive Deeper
VSTM:NASDAQ
Verastem Inc
$9.28
+7.66%
(+0.66) 1D
Oct 20, 3:11:13 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VSTM...
Open
$8.62
High
$9.47
Low
$8.57
Mkt. cap
1.13B
Avg. vol.
4.24M
Volume
2.78M
52-wk high
$10.82
52-wk low
$3.43
EPS
-$2.46
Beta
0.39
Shares outstanding
121.50M
No. of employees
102
Open
$8.62
High
$9.47
Low
$8.57
Mkt. cap
1.13B
Avg. vol.
4.24M
Volume
2.78M
52-wk high
$10.82
52-wk low
$3.43
EPS
-$2.46
Beta
0.39
Shares outstanding
121.50M
No. of employees
102
News stories
From web sources and news partners
Profile
Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index. Wikipedia
About Verastem Inc
CEOBrian Stuglik
Employees102
Founded2010
HeadquartersNeedham, Massachusetts, United States
SectorBiotechnology
Websiteverastem.com
Analyst ratings
Based on 7 analysts giving stock ratings to VSTM in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for VSTM in the last 3 months.
Highest
Current $9.28
$24.00 (+158.62%)
Average
$18.17 (+95.80%)
Lowest
$12.00 (+29.31%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jeet Mukherjee
BTIG
Buy
Maintained
$24.00
+158.6%
10/19/2026
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
$14.00
+50.9%
10/16/2026
Matthew Venezia
Alliance Global Partners
Buy
Maintained
$22.00
+137.1%
10/15/2026
Leonid Timashev
RBC Capital
Buy
Reiterated
$19.00
+104.7%
10/15/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
$18.00
+94%
10/16/2026
Kalpit Patel
Wolfe Research
Buy
Initiated
-
-
09/17/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$12.00
+29.3%
08/06/2026
James Molloy
Alliance Global Partners
Buy
Reiterated
$18.00
+94%
06/24/2026
Faisal Khurshid
Jefferies
Buy
Maintained
$8.00
-13.8%
06/23/2026
Unknown Analyst
B. Riley Securities
Buy
Initiated
$16.00
+72.4%
05/22/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
11.24M
17.54M
18.67M
40.08M
Cost of goods sold
1.67M
2.61M
2.77M
3.76M
Cost of revenue
1.67M
2.61M
2.77M
3.76M
Research and development expenses
28.99M
31.67M
38.22M
41.34M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
21.01M
24.44M
22.30M
27.41M
Operating expense
50.29M
56.40M
60.80M
69.03M
Total operating expenses
51.96M
59.01M
63.57M
72.79M
Operating income
-40.72M
-41.48M
-44.90M
-32.71M
Other non operating income
-58.67M
7.87M
7.39M
-1.90M
EBT including unusual items
-98.52M
-32.92M
-36.59M
-33.86M
EBT excluding unusual items
-98.52M
-32.92M
-36.59M
-33.86M
Income tax expense
-
-
-
816.00K
Effective tax rate
-
-
-
-2.41%
Other operating expenses
-
-
-
-
Net income
-98.52M
-32.92M
-36.59M
-34.67M
Net profit margin
-876.34%
-187.72%
-195.98%
-86.51%
Earnings per share
-0.54
-0.46
-0.43
-0.31
Interest and investment income
1.18M
1.10M
1.30M
1.11M
Interest expense
-319.00K
-415.00K
-382.00K
-360.00K
Net interest expenses
863.00K
689.00K
915.00K
748.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-40.42M
-41.18M
-44.62M
-32.43M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps